The incidence of lung cancer in the Moscow region from 1998 to 2018
https://doi.org/10.18093/0869-0189-2020-30-4-401-407
Abstract
This review discusses the main statistical indicators for lung cancer (LC) in the Moscow region over the past 20 years from 1998 to 2018. Methods. The analysis of basic statistics was carried out on the basis of official statistics of the Moscow region in the period from 1998 to 2018. Results. A decrease in the incidence was revealed. The five-year survival rate increased. The morphological diagnostics of LC improved. The detection of the disease in the early stages improved. In addition, mortality has decreased, both overall, and one-year. Conclusion. The reduction of morbidity and mortality, as well as the improvement of early detection of patients with LC in the Moscow Region was facilitated by the introduction of tobacco control measures, the implementation of programs to fight cancer, improving the quality of diagnostics and improving the equipment of clinics and hospitals, as well as the use of new modern treatment methods, such targeted and immunotherapy.
Supporting agencies: The study was carried out at the М.F.Vladimirskiy State Moscow Regional Research Clinical Institute in the framework of research study No. 72 «Immunohistochemical and molecular genetic predictors of the effectiveness of treatment and prognosis of the disease in patients with lung cancer»
About the Authors
M. M. Byakhova
M.F.Vladimirskiy State Moscow Regional Research Clinical Institute;
Russian Federal Academy of Continued Medical Education, Healthcare Ministry of Russia
Russian Federation
Russian Federation
Mariya M. Byakhova, Candidate of Medicine, Senior Researcher, Department оf Morphological Diagnostics, M.F.Vladimirskiy State Moscow Regional Research Clinical Institute, Associate Professor, Department of Pathological Anatomy, Russian Federal Academy of Continued Medical Education, Healthcare Ministry of Russia
ul. Shchepkina 61/2, Moscow, 129110,
ul. Barrikadnaya 2/1, build. 1, Moscow, 123995
S. N. Minakov
Oncology Coordination Center
Russian Federation
Russian Federation
Sergey N. Minakov, Candidate of Medicine
ul. Shchepkina 61/2, Moscow, 129110
G. A. Frank
Russian Federal Academy of Continued Medical Education, Healthcare Ministry of Russia
Russian Federation
Russian Federation
Georgiy A. Frank, Doctor of Medicine, Professor, Academician of of Russian Academy of Sciences, Head of Department of Pathological Anatomy
ul. Barrikadnaya 2/1, build. 1, Moscow, 123995
References
1. Bray F., Ferlay J., Soerjomataram I. et. al Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clin. 2018; 68 (6): 394–424. DOI: 10.3322/caac.21492.
2. Barta J.A., Powell C.A., Wisnivesky J.P. Global epidemiology of lung cancer. Ann. Global Health. 2019; 85 (1): 8. DOI: 10.5334/aogh.2419.
3. Wong M.C.S., Lao X.Q., Ho K.F. et al. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. Sci. Rep. 2017; 7: 14300. DOI: 10.1038/s41598-017-14513-7.
4. Merabishvili V.M., Arseniev A.I., Tarkov S.A. et al. [Lung cancer morbidity and mortality.] Sibirskiy onkologicheskiy zhurnal. 2018; 17 (6): 15–26. DOI: 10.21294/1814-4861-2018-17-6-15-26 (in Russian).
5. Ahmad O.B., Boschi-Pinto C., Lopez A.D. et al. Age standardization of rates: a new WHO standard. Geneva: World Health Organization; 2001. Available at: https://www.who.int/healthinfo/paper31.pdf?ua=1
6. Morris J.A., Gardner M.J. Statistics in medicine: Cal - culating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br. Med. J. (Clin. Res. Ed.). 1988; 296 (6632): 1313–1316. DOI: 10.1136/bmj.296.6632.1313.
7. Grimsrud T.K., Skaug H.K., Larsen I.K. Lung cancer – changes in incidence by gender, age and county of residence 1984–2013. Tidsskr. Nor. Laegeforen. 2015; 135 (20): 1844–1849. DOI: 10.4045/tidsskr.14.1424 (in English, Norwegian).
8. de Groot P.M., Wu C.C., Carter B.W., Munden R.F. The epidemiology of lung cancer. Transl. Lung Cancer Res. 2018; 7 (3): 220–233. DOI: 10.21037/tlcr.2018.05.06.
9. Scagliotti G.V., Parikh P., von Pawel J. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J. Clin. Oncol. 2008; 26 (21): 3543–3551. DOI: 10.1200/JCO.2007.15.0375.
10. Gretsova O.P., Petrova G.V., Starinskiy V.V. et al. [Estimation of the morphological verification index for the diagnosis of malignant neoplasm according to the data of the State Cancer Registry and to state statistical accounting forms]. Onkologiya. Zhurnal im. P.A.Gertsena. 2015; 4: 36– 39. DOI: 10.17116/onkolog20154436-39 (in Russian).
11. Petrova G.V., Gretsova O.P., Kaprin A.D., Starinskiy V.V. [Characteristics and methods of calculating medical and statistical indicators in oncology: Methodological guidelines]. Moscow: FGBU MNIOI im. P.A.Gertsena Minzdrava RF; 2014 (in Russian).
Review
For citations:
Byakhova M.M., Minakov S.N., Frank G.A. The incidence of lung cancer in the Moscow region from 1998 to 2018. PULMONOLOGIYA. 2020;30(4):401-407. (In Russ.) https://doi.org/10.18093/0869-0189-2020-30-4-401-407
Views:
607
Email this article 